Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Standard

Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis. / Goetze, Jens P.; Voiosu, Andrei; Wiese, Signe; Schulte, Janin; Kaufmann, Paul; Bergmann, Andreas; Bartels, Emil D.; Møller, Søren.

I: Biomarkers in Medicine, Bind 17, Nr. 13, 2023, s. 577-583.

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Harvard

Goetze, JP, Voiosu, A, Wiese, S, Schulte, J, Kaufmann, P, Bergmann, A, Bartels, ED & Møller, S 2023, 'Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis', Biomarkers in Medicine, bind 17, nr. 13, s. 577-583. https://doi.org/10.2217/bmm-2023-0337

APA

Goetze, J. P., Voiosu, A., Wiese, S., Schulte, J., Kaufmann, P., Bergmann, A., Bartels, E. D., & Møller, S. (2023). Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis. Biomarkers in Medicine, 17(13), 577-583. https://doi.org/10.2217/bmm-2023-0337

Vancouver

Goetze JP, Voiosu A, Wiese S, Schulte J, Kaufmann P, Bergmann A o.a. Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis. Biomarkers in Medicine. 2023;17(13):577-583. https://doi.org/10.2217/bmm-2023-0337

Author

Goetze, Jens P. ; Voiosu, Andrei ; Wiese, Signe ; Schulte, Janin ; Kaufmann, Paul ; Bergmann, Andreas ; Bartels, Emil D. ; Møller, Søren. / Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis. I: Biomarkers in Medicine. 2023 ; Bind 17, Nr. 13. s. 577-583.

Bibtex

@article{0f147f4ccb8e4f53ab065d51006b7a97,

title = "Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis",

abstract = "Background: Peptidylglycine α-amidating monooxygenase (PAM) is an enzyme involved in the maturation of regulatory peptides. Here we examined PAM activity and adrenomedullin (bio-ADM) concentrations in patients with hepatic cirrhosis and determined net changes across the liver, kidneys and leg. Materials and methods: A total of 48 patients with hepatic cirrhosis and 16 control subjects were included. All patients and controls underwent an invasive procedure with blood collected across organs. Results: PAM activity was increased in cirrhotic patients but without a net change across the liver, leg or kidney. In contrast, bio-ADM concentrations were associated with severity of disease and found to be higher in venous blood from the liver. Conclusion: Increased PAM activity in patients with hepatic cirrhosis may reflect other organs involved in cirrhotic disease. ",

keywords = "ADM, bioactive adrenomedullin, cirrhosis, heart failure, PAM, peptidylglycine α-amidating monooxygenase, proadrenomedullin",

author = "Goetze, {Jens P.} and Andrei Voiosu and Signe Wiese and Janin Schulte and Paul Kaufmann and Andreas Bergmann and Bartels, {Emil D.} and S{\o}ren M{\o}ller",

note = "Publisher Copyright: {\textcopyright} 2023 Future Medicine Ltd.",

year = "2023",

doi = "10.2217/bmm-2023-0337",

language = "English",

volume = "17",

pages = "577--583",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Future Medicine Ltd.",

number = "13",

}

RIS

TY - JOUR

T1 - Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis

AU - Goetze, Jens P.

AU - Voiosu, Andrei

AU - Wiese, Signe

AU - Schulte, Janin

AU - Kaufmann, Paul

AU - Bergmann, Andreas

AU - Bartels, Emil D.

AU - Møller, Søren

PY - 2023

Y1 - 2023

N2 - Background: Peptidylglycine α-amidating monooxygenase (PAM) is an enzyme involved in the maturation of regulatory peptides. Here we examined PAM activity and adrenomedullin (bio-ADM) concentrations in patients with hepatic cirrhosis and determined net changes across the liver, kidneys and leg. Materials and methods: A total of 48 patients with hepatic cirrhosis and 16 control subjects were included. All patients and controls underwent an invasive procedure with blood collected across organs. Results: PAM activity was increased in cirrhotic patients but without a net change across the liver, leg or kidney. In contrast, bio-ADM concentrations were associated with severity of disease and found to be higher in venous blood from the liver. Conclusion: Increased PAM activity in patients with hepatic cirrhosis may reflect other organs involved in cirrhotic disease.

AB - Background: Peptidylglycine α-amidating monooxygenase (PAM) is an enzyme involved in the maturation of regulatory peptides. Here we examined PAM activity and adrenomedullin (bio-ADM) concentrations in patients with hepatic cirrhosis and determined net changes across the liver, kidneys and leg. Materials and methods: A total of 48 patients with hepatic cirrhosis and 16 control subjects were included. All patients and controls underwent an invasive procedure with blood collected across organs. Results: PAM activity was increased in cirrhotic patients but without a net change across the liver, leg or kidney. In contrast, bio-ADM concentrations were associated with severity of disease and found to be higher in venous blood from the liver. Conclusion: Increased PAM activity in patients with hepatic cirrhosis may reflect other organs involved in cirrhotic disease.

KW - ADM

KW - bioactive adrenomedullin

KW - cirrhosis

KW - heart failure

KW - PAM

KW - peptidylglycine α-amidating monooxygenase

KW - proadrenomedullin

U2 - 10.2217/bmm-2023-0337

DO - 10.2217/bmm-2023-0337

M3 - Letter

C2 - 37812053

AN - SCOPUS:85176495130

VL - 17

SP - 577

EP - 583

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 13

ER -

ID: 387738745

Biomedicinsk Institut